- Trials with a EudraCT protocol (11)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
11 result(s) found for: Kynurenine.
Displaying page 1 of 1.
EudraCT Number: 2009-011990-34 | Sponsor Protocol Number: AFX02 | Start Date*: 2011-01-25 |
Sponsor Name:Clinic for Psychiatry and Psychotherapy of the Ludwig Maximilian University | ||
Full Title: Cytokines and Inflammatory Marker during Therapy in Major Depression with Celecoxib | ||
Medical condition: Major Depression | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-000112-21 | Sponsor Protocol Number: MESI-STRAT-WOO | Start Date*: 2018-09-03 | |||||||||||
Sponsor Name:Ruprecht-Karls-Universität Heidelberg, Medizinische Fakultät, vertreten durch das Universitätsklinikum Heidelberg | |||||||||||||
Full Title: Prospective Window of opportunity trial 3 weeks neoadjuvant Anastrozole in Postmenopausal Women with Estrogen receptor positive (ER+) Breast Cancer | |||||||||||||
Medical condition: (ER+) Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003960-22 | Sponsor Protocol Number: WOO2 | Start Date*: 2021-03-15 | |||||||||||
Sponsor Name:Medical University of Innsbruck | |||||||||||||
Full Title: Prospective Window of opportunity trial of 3 weeks neoadjuvant Anastrozole in Postmenopausal Women with Estrogen receptor positive (ER+) Breast Cancer | |||||||||||||
Medical condition: (ER+) Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000199-41 | Sponsor Protocol Number: GESIDA10918 | Start Date*: 2019-07-10 | |||||||||||
Sponsor Name:Fundación SEIMC-GESIDA | |||||||||||||
Full Title: A phase IV, multicenter, open and randomized study to evaluate the impact of the change of antiretroviral treatment from dual therapy to triple therapy on inflammation in patients with type 1 HIV i... | |||||||||||||
Medical condition: HIV | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003930-10 | Sponsor Protocol Number: KEKU1 | Start Date*: 2018-01-12 |
Sponsor Name:Recherche et enseignement en douleur, anesthesie reanimation | ||
Full Title: KETAMINE'S EFFICIENCY IN THE TREATMENT OF CHRONIC PAIN WITH INFLAMMATORY COMPONENT: EXPLORING THE KYNURENIN PATHWAYS. A controlled, placebo-controlled, double-blind trial. | ||
Medical condition: The population selected is a spinal cord injury population with central neuropathic pain at the lesional or sub-lesion level, chronically (for more than three months) Adult, spinal cord injury (SCI... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001539-39 | Sponsor Protocol Number: NV18-04-00260 | Start Date*: 2019-06-17 |
Sponsor Name:Národní ústav duševního zdraví | ||
Full Title: Clinical and neurobiological predictors of response to ketamine: towards personalized treatment of depression | ||
Medical condition: Moderate to severe depression without psychotic symptoms | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-003413-26 | Sponsor Protocol Number: MINDEP | Start Date*: 2015-12-14 | |||||||||||
Sponsor Name:King's College London [...] | |||||||||||||
Full Title: Understanding the molecular basis for the use of adjunctive anti-inflammatory treatment in treatment resistant depression: a stratified, randomised, placebo-controlled, experimental medicine study ... | |||||||||||||
Medical condition: Depression | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003858-85 | Sponsor Protocol Number: HFIRONT | Start Date*: 2020-02-24 |
Sponsor Name:Medical University Innsbruck | ||
Full Title: Randomized double-blind explorative controlled clinical trial analyzing the effects of ferric carboxymaltose in patients with iron deficiency and chronic heart failure | ||
Medical condition: This is a randomized double-blind explorative controlled clinical Trial that analyses the effects of 1000mg ferric carboxymaltose in patients with chronic heart failure and iron deficiency. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-002366-13 | Sponsor Protocol Number: IB2020-02 | Start Date*: 2021-12-20 | |||||||||||
Sponsor Name:Institut Bergonié | |||||||||||||
Full Title: Combination of pembrolizumab and cabozantinib in patients with advanced sarcomas | |||||||||||||
Medical condition: Advanced /metastatic sarcomas: undifferentiated pleomorphic sarcoma, osteosarcoma and Ewing sarcoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005609-34 | Sponsor Protocol Number: CNIO-BR-008 | Start Date*: 2016-04-26 | |||||||||||
Sponsor Name:Fundación CRIS de investigación para vencer el cáncer | |||||||||||||
Full Title: Abrogation of chronic monoclonal antibody treatment-induced T-cell exhaustion with DURVALUMAB (MEDI4736) in advanced HER-2 negative breast cancer: a pilot proof-of-concept trial | |||||||||||||
Medical condition: Advanced HER-2 negative breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000878-11 | Sponsor Protocol Number: OMO1.01.02 | Start Date*: 2017-06-08 | |||||||||||
Sponsor Name:OCTIMET Oncology NV | |||||||||||||
Full Title: A modular, multi-arm, multi-part, first time in patient study to evaluate the safety and tolerability of OMO-1, alone and in combination with anti-cancer treatments, in patients with locally advanc... | |||||||||||||
Medical condition: Locally advanced, unresectable or metastatic solid malignancies | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) NL (Prematurely Ended) BE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
